Sorghum Bicolor Pollen

The dosage for Sorghum Bicolor Pollen allergenic extract is highly individualized and must be determined by an allergy specialist. There is no 'one-size-fits-all' dose because each patient's level of sensitivity varies significantly. Dosing is typically divided into two phases:

1. 1Build-up Phase (Escalation Phase): This phase starts with a very low dose of a highly diluted extract (e.g., 0.05 mL of a 1:100,000 w/v dilution). Injections are usually given 1 to 2 times per week. The dose is gradually increased at each visit based on the patient's local and systemic tolerance. This phase typically lasts 3 to 6 months.
2. 2Maintenance Phase: Once the 'top dose' or maximum tolerated dose is reached, the frequency of injections is decreased to once every 2 to 4 weeks. The maintenance dose is intended to provide long-term immunological suppression of the allergic response. This phase generally continues for 3 to 5 years.

Sorghum Bicolor Pollen extracts may be used in children, typically starting at age 5 and older. The dosing schedule for pediatric patients follows the same principles as adult dosing, starting with very low concentrations and gradually increasing. Pediatric patients require close monitoring, as they may be less able to articulate the early symptoms of a systemic reaction. Healthcare providers must carefully assess the child's weight and overall health before each injection.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the extract is not cleared through the kidneys in a manner that would lead to systemic toxicity. However, the patient's overall health should be stable before administration.

Hepatic Impairment

No specific adjustments are necessary for hepatic impairment. The metabolism of allergenic proteins occurs via local tissue proteolysis and is not dependent on hepatic CYP450 enzymes.

Elderly Patients

Caution is advised in elderly patients, particularly those with underlying cardiovascular disease. The use of epinephrine (the primary treatment for a severe reaction) may be riskier in this population. Healthcare providers should perform a thorough risk-benefit analysis before starting immunotherapy in patients over 65.

Sorghum Bicolor Pollen extract for immunotherapy MUST be administered by a healthcare professional in a clinical setting equipped to handle anaphylaxis. It is never for self-administration at home.

• Preparation: The healthcare provider will check the vial concentration and expiration date. The injection site (usually the back of the upper arm) is cleaned with alcohol.
• Administration: The injection is given subcutaneously. The provider will ensure the needle is not in a blood vessel by aspirating before injecting.
• Observation: After the injection, the patient must remain in the clinic for at least 30 minutes. Most life-threatening systemic reactions occur within this window.
• Storage: Extracts should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.

If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated to maintain safety. If a dose is missed during the maintenance phase, the healthcare provider will decide whether to repeat the last dose or reduce it based on how much time has passed (e.g., if more than 4 weeks have passed since the last maintenance dose). Never attempt to 'double up' on doses to catch up.

An 'overdose' in the context of allergenic extracts refers to receiving a dose higher than the patient's current tolerance level, which can lead to a systemic allergic reaction or anaphylaxis.

• Signs of Overdose/Reaction: Hives, itching, swelling of the throat, wheezing, shortness of breath, drop in blood pressure, or rapid heart rate.
• Emergency Measures: Immediate administration of epinephrine, oxygen, and antihistamines. Emergency medical services must be contacted if the reaction occurs outside a hospital setting.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your schedule or skip doses without medical guidance, as this increases the risk of a reaction when treatment resumes.

Most patients receiving Sorghum Bicolor Pollen immunotherapy will experience some form of local reaction. These are generally not dangerous but can be uncomfortable.

• Local Redness (Erythema): A red patch at the site of the injection, similar to a mosquito bite.
• Local Swelling (Edema): A raised bump or 'wheal' at the injection site. If the swelling is larger than a half-dollar (approx. 3 cm), your doctor may adjust your next dose.
• Itching (Pruritus): Intense itching at the site of the injection is common and usually subsides within a few hours.
• Tenderness: The area may feel sore or warm to the touch for 24 to 48 hours.

• Large Local Reactions: Swelling that extends beyond the immediate injection site, sometimes involving the entire upper arm. This may require the use of ice packs or oral antihistamines.
• Mild Systemic Symptoms: Some patients may feel a general sense of fatigue, mild sneezing, or a 'stuffy' nose shortly after the injection.
• Headache: A transient headache may occur following the administration of allergenic extracts.

• Hives (Urticaria): Generalized hives appearing on parts of the body away from the injection site. This is a sign of a systemic reaction.
• Angioedema: Swelling deep in the skin, often around the eyes or lips.
• Persistent Fatigue: Some patients report feeling 'flu-like' symptoms for a day or two following their maintenance dose.

> Warning: Stop taking Sorghum Bicolor Pollen and call your doctor immediately or seek emergency care if you experience any of these symptoms of anaphylaxis.

• Difficulty Breathing: Wheezing, chest tightness, or a feeling of 'air hunger.'
• Throat Tightness: A feeling that the throat is closing or difficulty swallowing.
• Hypotension (Low Blood Pressure): Feeling faint, dizzy, or passing out. This can be a sign of circulatory collapse.
• Rapid or Weak Pulse: A heart rate that feels significantly faster than normal or difficult to find.
• Nausea and Vomiting: Sudden gastrointestinal distress can be a component of a systemic allergic reaction.
• Cyanosis: A bluish tint to the lips or fingernails, indicating a lack of oxygen.

Allergen immunotherapy is generally considered safe for long-term use (3-5 years). There is no evidence that long-term use of Sorghum Bicolor Pollen extract increases the risk of autoimmune diseases or cancer. Some patients may develop a new sensitivity to other allergens during the course of treatment, though this is rare and usually unrelated to the extract itself. The most significant long-term 'effect' is the desired reduction in allergy symptoms and a decreased risk of developing asthma in children with allergic rhinitis.

Sorghum Bicolor Pollen extracts, like all allergenic extracts, carry a significant risk of severe systemic reactions. While not always presented in a literal 'black box' on every non-standardized label, the FDA requires the following safety information to be prominently displayed:

WARNING: RISK OF SEVERE ALLERGIC REACTIONS

• Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis.
• This product must only be administered by physicians who are experienced in the treatment of allergic diseases and the management of anaphylaxis.
• Patients must be observed for at least 30 minutes in the office after receiving an injection.
• Immunotherapy should not be initiated or escalated in patients with unstable or severe asthma.
• Patients taking beta-blockers may be more resistant to the effects of epinephrine if a reaction occurs.

Report any unusual symptoms, especially those occurring hours after the injection, to your healthcare provider immediately.

Sorghum Bicolor Pollen immunotherapy is a medical procedure that involves the deliberate exposure of a sensitive patient to an allergen. Because of this, safety is the paramount concern. Patients must be in good health at the time of each injection. If you have a fever, a cold, or an active asthma flare-up, your injection should be postponed. Always inform your nurse or doctor about any new medications or changes in your health status since your last visit.

No specific 'Black Box' warning is uniquely assigned to Sorghum Bicolor Pollen beyond the class-wide warning for all allergenic extracts. This warning emphasizes that these products can cause anaphylaxis, which can be fatal. Administration must occur in a facility where emergency equipment, including oxygen, IV fluids, and epinephrine, is immediately available. Patients must be informed of the risks and remain under medical supervision for the required 30-minute observation period.

• Anaphylaxis Risk: This is the most significant risk. Anaphylaxis is a multi-systemic, potentially lethal allergic reaction. Risk factors include high levels of sensitivity, rapid dose escalation, and administration during peak pollen season.
• Asthma Status: Patients with uncontrolled asthma are at the highest risk for fatal reactions to immunotherapy. Your doctor will likely check your peak flow or ask about your asthma symptoms before every injection.
• Cardiovascular Disease: Patients with significant heart disease may not be able to tolerate the physiological stress of a systemic reaction or the effects of the epinephrine used to treat it.
• Autoimmune Disorders: There is a theoretical concern that immunotherapy could exacerbate certain autoimmune conditions, although data on this is limited. Use with caution in these populations.

There are no routine laboratory tests (like blood counts or liver panels) required specifically for Sorghum Bicolor Pollen. However, monitoring includes:

• Pre-injection Assessment: Checking for symptoms of asthma or infection.
• Post-injection Observation: 30-minute mandatory wait time to monitor for immediate systemic reactions.
• Injection Site Inspection: Checking for large local reactions that might necessitate a dose adjustment.
• Periodic Review: Every 6-12 months, the allergist will evaluate the efficacy of the treatment and determine if the maintenance dose is appropriate.

Most patients can drive and operate machinery after their 30-minute observation period. However, if you experience dizziness, fatigue, or any systemic symptoms after your injection, you should avoid these activities and contact your doctor.

It is generally recommended to avoid alcohol for several hours before and after your allergy injection. Alcohol can cause vasodilation (widening of the blood vessels), which may increase the rate of allergen absorption and potentially increase the risk of a systemic reaction.

Immunotherapy is typically discontinued after 3 to 5 years of successful maintenance. There is no 'withdrawal syndrome' associated with stopping Sorghum Bicolor Pollen. However, if treatment is stopped prematurely, allergy symptoms are likely to return. If you wish to stop treatment, discuss a tapering or cessation plan with your allergist.

> Important: Discuss all your medical conditions, especially respiratory or heart problems, with your healthcare provider before starting Sorghum Bicolor Pollen.

There are few absolute contraindications for drug combinations, but the following are considered highly risky:

• Non-Selective Beta-Blockers (e.g., Propranolol): These drugs can make a systemic allergic reaction much more severe and, more importantly, can make the patient's body resistant to the life-saving effects of epinephrine. If you are on a beta-blocker, your doctor may require you to switch to a different blood pressure medication before starting immunotherapy.

• Selective Beta-Blockers (e.g., Atenolol, Metoprolol): While slightly safer than non-selective ones, they still pose a risk of interfering with anaphylaxis treatment.
• ACE Inhibitors (e.g., Lisinopril): Some studies suggest that patients on ACE inhibitors may be at an increased risk for more severe systemic reactions during immunotherapy, possibly due to the role of bradykinin in allergic responses.
• MAO Inhibitors (MAOIs): These can potentiate the effects of epinephrine, leading to dangerously high blood pressure if an emergency injection is required.

• Tricyclic Antidepressants (TCAs): Similar to MAOIs, TCAs can increase the cardiovascular response to epinephrine.
• Antihistamines: While often used to manage local reactions, taking a strong antihistamine right before a skin test will cause a false-negative result. For immunotherapy, they can sometimes mask the early 'warning signs' of a systemic reaction.

There are no specific food interactions with Sorghum Bicolor Pollen extract. However, patients should avoid heavy meals or very hot beverages immediately before an injection, as these can increase core body temperature and blood flow, potentially altering the absorption of the extract.

There is limited data on herbal interactions. However, any supplement that affects the immune system (such as high-dose Echinacea) or blood pressure should be discussed with your allergist. St. John's Wort may interact with various medications used to treat allergic reactions.

• Skin Prick Tests: The most significant interaction is with medications that suppress the skin's response to histamine. This includes H1-antihistamines (like cetirizine or loratadine), certain antidepressants, and topical steroids at the test site. These must be stopped for several days (or weeks, depending on the drug) before diagnostic testing with Sorghum Bicolor Pollen.
• Total IgE and Specific IgE Tests: Immunotherapy will eventually lead to changes in these lab values (often an initial rise in specific IgE followed by a long-term decline), but the extract itself does not interfere with the performance of the blood test.

For each major interaction, the primary concern is either an increased risk of a severe allergic reaction or a decreased ability to treat such a reaction if it occurs. Management usually involves switching to safer alternative medications for blood pressure or depression before beginning the immunotherapy course.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter allergy pills.

Sorghum Bicolor Pollen extract must NEVER be used in the following circumstances:

1. 1Severe or Uncontrolled Asthma: Patients with a forced expiratory volume in 1 second (FEV1) consistently below 70% of predicted, or those with frequent acute exacerbations, are at an unacceptably high risk for fatal anaphylaxis.
2. 2Previous Severe Reaction to This Specific Extract: If a patient has had a near-fatal reaction to Sorghum Bicolor Pollen in the past, the risks of continuing immunotherapy usually outweigh the benefits.
3. 3Hypersensitivity to Excipients: Some extracts contain phenol or glycerin as preservatives. Patients with a known severe allergy to these components should not receive the extract.
4. 4Inability to Communicate: Patients who cannot report symptoms of a reaction (e.g., very young children or those with certain cognitive impairments) may not be suitable candidates for SCIT.

These conditions require a careful risk-benefit analysis by the allergist:

• Active Autoimmune Disease: Conditions like systemic lupus erythematosus (SLE) or rheumatoid arthritis may be worsened by the immune stimulation of immunotherapy.
• Malignancy: Patients undergoing active cancer treatment generally should not start immunotherapy.
• Beta-Blocker Therapy: As discussed, this makes treating a reaction difficult.
• Pregnancy (Initiation): It is standard practice not to start immunotherapy during pregnancy due to the risk of anaphylaxis causing fetal hypoxia (lack of oxygen to the baby).

Sorghum Bicolor is a grass. Patients sensitive to Sorghum Bicolor Pollen often show cross-reactivity with other members of the Poaceae family, such as Johnson Grass, Corn pollen, and Sugar Cane pollen. This means that a patient allergic to one may react to others. Your doctor will use this information to create a 'cocktail' of allergens if you are sensitive to multiple grasses.

> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and current medications, before prescribing Sorghum Bicolor Pollen.

Sorghum Bicolor Pollen is classified as FDA Pregnancy Category C. This means that adequate animal reproduction studies have not been conducted, and it is not known whether the extract can cause fetal harm.

• Initiation: Healthcare providers generally do not start new immunotherapy during pregnancy.
• Maintenance: If a woman is already on a stable maintenance dose and becomes pregnant, the treatment is usually continued, as the risk of a reaction is lower once maintenance is reached. However, the dose is typically not increased during the pregnancy.
• Risk: The primary risk to the fetus is maternal anaphylaxis, which can lead to a sudden drop in blood pressure and oxygen delivery to the placenta.

It is generally considered safe to continue Sorghum Bicolor Pollen immunotherapy while breastfeeding. The allergenic proteins are broken down locally and are unlikely to pass into breast milk in any significant or harmful quantity. There are no known adverse effects on the nursing infant.

Immunotherapy with Sorghum Bicolor Pollen is effective in children, particularly for preventing the 'allergic march' (the progression from allergic rhinitis to asthma).

• Age: Most allergists wait until a child is at least 5 years old so they can adequately communicate if they are feeling the symptoms of a reaction.
• Benefits: Studies have shown that grass pollen immunotherapy can provide long-lasting relief and reduce the need for daily medications in children.

Patients over the age of 65 may be at higher risk for complications from immunotherapy.

• Cardiovascular Health: The elderly are more likely to have underlying heart disease, making them more vulnerable to the effects of anaphylaxis or the epinephrine used to treat it.
• Polypharmacy: Older patients are often on multiple medications (like beta-blockers or ACE inhibitors) that can interact with the extract or its emergency treatment.

There are no specific guidelines for Sorghum Bicolor Pollen use in renal impairment. Since the extract works locally and through the immune system rather than being cleared by the kidneys, standard dosing is typically used. However, patients with end-stage renal disease should be monitored for overall physiological stability.

No adjustments are needed for patients with liver disease. The processing of the allergens does not involve the liver's metabolic pathways.

> Important: Special populations require individualized medical assessment. Always inform your allergist if you are pregnant, planning to become pregnant, or have any chronic health conditions.

Sorghum Bicolor Pollen extract acts as an immunomodulator. The primary allergens in the pollen (often proteins in the expansin or profilin families) are recognized by the immune system. In an allergic individual, this recognition is mediated by IgE. Immunotherapy changes this by:

• T-cell Deviation: Shifting the T-helper cell response from Th2 (pro-allergic) to Th1 (anti-allergic).
• Treg Induction: Increasing the number of CD4+ CD25+ regulatory T-cells, which secrete IL-10. IL-10 reduces IgE production and increases IgG4 production.
• B-cell Modulation: Encouraging B-cells to produce 'blocking' IgG4 antibodies that neutralize the pollen allergens before they can reach the IgE on mast cells.

The pharmacodynamic effect of Sorghum Bicolor Pollen is not immediate.

• Onset: It typically takes 3 to 6 months of build-up before a patient notices a reduction in symptoms.
• Duration: The effects can last for several years after the 3-5 year course of treatment is completed.
• Tolerance: The goal is the development of long-term clinical tolerance to Sorghum pollen.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Local SC injection) |

| Protein Binding | N/A (Immunological processing) |

| Half-life | N/A (Biological degradation) |

| Tmax | 30-60 minutes (for systemic absorption) |

| Metabolism | Local Proteolysis |

| Excretion | Cellular waste |

• Composition: A complex mixture of proteins, glycoproteins, and polysaccharides.
• Molecular Weight: Ranges from 10 kDa to over 70 kDa for major allergens.
• Solubility: Highly soluble in aqueous buffers and saline.
• Source: Collected from the anthers of Sorghum bicolor plants during peak flowering.

Sorghum Bicolor Pollen is classified as a Non-Standardized Pollen Allergenic Extract. It is related to other grass extracts like Timothy Grass, Kentucky Bluegrass, and Johnson Grass. Unlike 'Standardized' extracts (like Timothy), non-standardized extracts do not have a federally mandated potency test relative to a national standard vial, so their strength is expressed in PNU or w/v.